Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
Enzyme replacement therapy (ERT) with recombinant α-galactosidase A (AGAL) can lead to the formation of neutralizing anti-drug antibodies (ADA), which significantly limit treatment efficacy in patients with Fabry disease (FD). The effects of dose escalation on ADA titer and plasma globotriaosylsphin...
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Frontiers Media S.A.
2022-12-01
|
| Saila: | Frontiers in Immunology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1024963/full |